However, evidence on the association between rifaximin therapy and the structure of circulating albumin in patients with cirrhosis is limited, and to our knowledge, this is the first study to investigate the structure of circulating albumin during rifaximin therapy. This evidence concerns the gene ALB and Cirrhosis.